AstraZeneca reports positive Phase III study
AstraZeneca PLC on Monday reported a positive result in a Phase III study of its thyroid cancer drug.
UK pharmaceutical giant AstraZeneca was downgraded to underweight from neutral on Monday at JP Morgan, which said the company has a strong track record of beating estimates, but this will get tougher in coming quarters as it has to digest generic competition of high-margin products.